Press Releases for AMGN

Press Releases
Cytokinetics Announces Addition to Board of Directors
NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance
State AGs suing U.S. drug maker Amgen
SaaS Leader Daptiv Adds Amdocs and Microsoft Veteran Chase Franklin As CEO
GENova Biotherapeutics (GVBP) SqueezeTrigger Price is $0.43. Approximately 57 Million Shares Shorted Since July 2009 According to Buyins.Net Research Report
Symyx Joins SAFE-BioPharma to Ensure Safe Security Standards for ELN Software; Pharmaceutical Industry Non-Profit Maintains Standards and Certification for Digital Signatures
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
Fusing Science and Society: Media Entrepreneur Adam Bly Launches National Biotechnology Week in London, Ontario
BenchmarkJournal.Com Free Analyst Review for HCBK, PLCE, GNTX, AMGN, NPBC and LAMR
Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
Partial approval for Amgen bone drug
Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
StockPreacher.com Issues Trading Outlook for Nabi Biopharmaceuticals
Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
StockPreacher.Com Issues Trading Outlook for Keryx Biopharmaceuticals Inc.
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Celldex Reports Second Quarter and Six Month 2009 Financial Results
Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Amgen Co-Founder to Act As Generex Chief Scientific Advisor; Generex Engages Dr. Joseph Rubinfeld to Spearhead the Company's Scientific Development and Commercialization Plans for Its Drug Delivery Platform and Vaccine Technologies
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
Cytokinetics, Incorporated Reports Second Quarter 2009 Financial Results
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
StockPreacher.com Issues Trading Outlook for Onyx Pharmaceuticals Inc. (ONXX)
Amgen Announces Webcast of 2009 Second Quarter Financial Results
Baucus reels in big healthcare donations
Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors
InvestorSoup.Com Researches: DynCorp, Amazon, Las Vegas Sands, Family Dollar and Amgen
Integrity Media Identifies Market Actives: IFSL, GRVY, NVGN, AMGN, THC, DCP, FDO
Integrity Media Identifies Market Actives: IFSL, GRVY, NVGN, AMGN, THC, DCP, FDO
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
MattsonJack Adds Indications to Epi Database
Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
SAFE-BioPharma Changes Fees to Help Clinical Investigators, CROs, Others
ImmunoGen, Inc. Announces Exercise of Over-Allotment Option
S&P 500 Stock Buybacks Retreat 73% in the First Quarter; Lowest Since Second Quarter of 2003
34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
June 23 DIA Sessions Chaired By SAFE-BioPharma Association
Amgen to Present at the Goldman Sachs Global Healthcare Conference
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP
miRagen Therapeutics, Inc. Accomplishes Funding Milestones and Secures Series A Extension
ARIAD Announces Updates On NF-ÎºB Patent Appeals
Biotech Shows Glimmer of an Upward Trend
Pressure BioSciences, Inc. (PBIO) Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
Marketwire to Be Official Newswire of ExL Pharma's 5th PR &Amp; Communications Summit
VIDEO from Medialink and Amgen: New Survey Highlights Growing Concern About Risk of Infection and Emerging Antibiotic Resistance in Cancer Patients
New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Cytokinetics Announces Registered Direct Common Stock Offering of $14.0 Million
Amgen Highlights Data to Be Presented at ASCO
Accelerator Corporation Announces XORI Corporation
EPIX Pharmaceuticals Announces Receipt of NASDAQ Panel Decision to Delist Common Stock
Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
Orange County Venture Group Hosts "Obamanomics" Panel Discussion
MattsonJack to Present at Access to Innovative Cancer Therapies in 2009 - 4th Annual Oncology Economics Forum
Halozyme Therapeutics Reports First Quarter 2009 Financial Results
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
Celldex Reports First Quarter 2009 Financial Results
ThirdAge.Com Selects Interevco to Sell Its Online Advertising
Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Wyeth Reports Earnings Results for the 2009 First Quarter
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
MattsonJack Hires Gary Sullivan, Augments Business Development Expertise
Amgen Announces Webcast of 2009 First Quarter Financial Results
Recycling Crisis This Earth Day
Premier Oracle Publication Features Brainware Customer Success Story
Former NASDAQ Executive Joins Board of Directors of InsideVenture
MattsonJack to Lead Workshop at Pharmaceutical Strategic Outlook and BIO-Windhover
Amgen to Present at the Citigroup Biotech Day
Zacks Analyst Blog Highlights: Cognizant Technology Solutions Corp., Infosys Technologies, Ltd., Wipro Ltd., Amgen, Inc. And AK Steel - Mar 27 2009 11:55PM
Zacks Analyst Blog Highlights: Cognizant Technology Solutions Corp., Infosys Technologies, Ltd., Wipro Ltd., Amgen, Inc. And AK Steel - Mar 27 2009 7:00AM
S&P 500 Stock Buybacks Retreat 66% in Fourth Quarter; Off 42% in 2008 - Mar 26 2009 11:36AM
QLT Names Kathryn Falberg to the Board of Directors
Zacks Analyst Blog Highlights: Vivo Participacoes, America Movil, TIM Participacoes, Amylin Pharmaceuticals, Inc. And Eli Lilly.
Capacity Crowd at 2009 Southeast Venture Conference Optimistic About Market - Mar 19 2009 6:53PM
Capacity Crowd at 2009 Southeast Venture Conference Optimistic About Market - Mar 19 2009 2:52PM
Dyax Amends Loan Agreement With Cowen Healthcare Royalty Partners for an Additional $15 Million
Amgen to Present at the Cowen and Company Annual Healthcare Conference
Wall Street News Alert: 4 Stocks You Need to Know for Friday! March 13, 2009
Media Invite - The Pacific Northwest's Largest Life Sciences Investment Conference, March 17-18, 2009
Amgen to Present at the Barclays Capital Global Healthcare Conference
Galapagos Confirms 2008 Financial Results, Foresees Strong Growth in 2009
Photos: 'Project Runway's' Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldn't Let Psoriasis Impact Personal Style
MattsonJack to Present at Cancer Progress Conference: Pricing Issues in a Strained Economy
EPIX Pharmaceuticals Announces Resignation of Chief Business Officer - Feb 27 2009 11:52PM
MattsonJack Forecasting Workshop Addresses Critical Issues in Pharmaceutical Forecasting
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
Gold Partners Appoints Larry Bell, M.D. President, Regulatory, Quality, Safety and Risk Management Services
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Animax Launches Division Dedicated to Health Sector
MattsonJack to Present at Impact of Medicare Reform in 2009 - 5th Annual Oncology Economics Summit
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
BenchmarkJournal.Com (Complimentary) Analyst Updates for AMGN, ORCL, JNPR and LVLT
Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services